#USA #San Francisco #Zabalafin Hydrogel #Alphyn Biologics #Neal Koller

Alphyn Biologics to Present at Upcoming Investor Conferences

Alphyn Biologics, a pioneering firm in the realm of dermatology, is preparing to make significant strides in its investor engagement through several conferences held during J.P. Morgan Healthcare Week in San Francisco. Neal Koller, the CEO of Alphyn, will lead the company's presentations at key industry events including the Biotech Showcase and NEXUS 2025.

The first presentation will take place on January 13 at 10:45 a.m. at the Hilton San Francisco Union Square during the Biotech Showcase. This event is focused on emerging biotech innovations, making it a prime venue for Alphyn to introduce its cutting-edge pipeline. Following this, on January 14 at 11 a.m., Koller will participate as a finalist in the Redefining Every Stage of Investment (RESI) conference hosted at the San Francisco Marriott Marquis. At this event, he will have the opportunity to present Alphyn’s unique business model and therapeutic innovations to seasoned investors and industry experts.

The day will continue with Koller’s presentation at the NEXUS 2025 event from 3 p.m. to 9 p.m. at The Hangar in South San Francisco, providing additional exposure to venture capitalists and potential partners. At these conferences, Koller will deliver an overview of the company’s operations, particularly spotlighting its lead product candidate, Zabalafin Hydrogel.

Zabalafin Hydrogel is being developed as a transformative solution for Atopic Dermatitis (AD), a condition marked by chronic inflammation and discomfort for patients. The therapeutic mechanism of Zabalafin stands out as it aims not only to alleviate itching but also to tackle the very bacterial infections that exacerbate inflamed skin, thus addressing multiple facets of the ailment. Koller’s presentation will delve into the latest advancements in clinical trials, including plans for the onset of Phase 2b trials later this year. This promising development aligns with Alphyn's commitment to innovate in dermatological treatment through its platform designed to target multiple pathways.

Alphyn’s approach to dermatology is centered on the Zabalafin Platform, which comprises several bioactive compounds, each contributing to diverse mechanisms of action. This structure positions the company to create a robust pipeline that can meet the varied needs of patients suffering from severe skin conditions. Furthermore, the platform has demonstrated promising results in prior clinical trials, indicating its potential as a long-term solution that is both safe and effective for continuous usage.

Having initiated operations in 2020, Alphyn Biologics has garnered a reputation for innovation in the dermatology space, raising approximately $16 million in funding to support its research and development efforts. With its headquarters strategically located in Annapolis, Maryland, and Cincinnati, Ohio, along with fully owned subsidiaries in Australia and Austria, Alphyn is poised to make a substantial impact on the global dermatological landscape.

In anticipation of these presentations, industry observers are keen to see how Koller’s insights on the future of Zabalafin Hydrogel will resonate with potential investors and collaborators. The developments at these conferences not only spotlight Alphyn’s products but also herald a new chapter in dermatological care that could significantly improve the quality of life for those afflicted by skin diseases.

Stay tuned for updates on the outcomes of these pivotal events as Alphyn outlines its vision for advancing dermatological therapeutics.